Multi-center, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 16 μg LNG/Day Initial in Vitro Release Rate (LCS16) in Comparison to a Combined Oral Contraceptive (COC) Containing 30 μg Ethinyl Estradiol and 3 mg Drospirenone (Yarina®) in Young Nulliparous and Parous Women (18 - 29 Years) Over 12 Months of Use (With an Option for Extended Use of LCS16 for up to 5 Years)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Levonorgestrel (Primary) ; Drospirenone/ethinylestradiol
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 19 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2017 Status changed from not yet recruiting to recruiting.
- 10 Mar 2017 New trial record